Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating.
The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this revived concerns about whether Haleon was investing enough behind growth.
Haleon shares rose 0.28% to 364.10p in morning trading on Monday, after opening at 363.10p, with the stock reaching an intraday high of 364.50p.
Haleon delivered organic sales growth of 3.1% in the second quarter, split between a 1.7% rise in prices and a 1.4% increase in volumes.
Oral Health grew 6.2%, driven by the Sensodyne and Parodontax brands, while Pain Relief accelerated 4.6% on Voltaren gel expansion.
#Health #NYSE
The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this revived concerns about whether Haleon was investing enough behind growth.
Haleon shares rose 0.28% to 364.10p in morning trading on Monday, after opening at 363.10p, with the stock reaching an intraday high of 364.50p.
Haleon delivered organic sales growth of 3.1% in the second quarter, split between a 1.7% rise in prices and a 1.4% increase in volumes.
Oral Health grew 6.2%, driven by the Sensodyne and Parodontax brands, while Pain Relief accelerated 4.6% on Voltaren gel expansion.
#Health #NYSE
1 month ago
